BIO|STREAM.CSP CLS
Observation of Clinical Routine Care for Patients Implanted With BIOTRONIK Devices Used for Conduction System Pacing (CSP) With Focus on Closed Loop Stimulation (CLS)
This clinical study is a prospective, observational submodule of the BIO|STREAM.CSP registry designed to evaluate clinical outcomes in patients receiving BIOTRONIK dual-chamber pacemakers that combine conduction system pacing-specifically left bundle branch area pacing (LBBAP)-with Closed Loop Stimulation (CLS). The purpose of the study is to better understand how this combined pacing strategy performs in routine clinical practice and whether it may help reduce the occurrence of atrial fibrillation in patients with sinus node dysfunction (SND) and concomitant atrioventricular (AV) conduction disorders.
The primary question the study seeks to answer is what the incidence of device-detected atrial fibrillation (DDAF) is over a 24-month follow-up period in patients treated with LBBAP and active CLS. Additionally, the study explores how CLS dynamically modulates pacing rates when the ventricular lead is positioned within the conduction system, and whether this physiological pacing approach may mitigate the negative effects associated with conventional right ventricular pacing.
Overall, this study aims to generate real-world evidence to support optimization of pacemaker programming and to inform clinical decision-making regarding the use of CLS in combination with conduction system pacing, with the goal of improving patient outcomes and reducing atrial arrhythmia burden.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This study, BIO|STREAM.CSP CLS, is a prospective, observational submodule of the ongoing BIO|STREAM.CSP registry. It is designed to collect real-world clinical data from patients who receive BIOTRONIK dual-chamber pacemakers using conduction system pacing (CSP), with a specific focus on the combination of left bundle branch area pacing (LBBAP) and Closed Loop Stimulation (CLS).
Permanent cardiac pacing is a standard therapy for patients with sinus node dysfunction (SND), a condition in which the heart's natural pacemaker does not function properly. A considerable proportion of these patients also have atrioventricular (AV) conduction disorders, which impair the electrical connection between the atria and ventricles. In such cases, dual-chamber pacemakers are typically implanted to maintain appropriate heart rhythm and coordination.
Traditional right ventricular (RV) pacing, while effective in maintaining heart rate, has been associated with non-physiological activation of the heart and may contribute to an increased risk of atrial fibrillation (AF), especially when pacing burden is high. Device-detected atrial fibrillation (DDAF) is a clinically relevant outcome, as it is associated with increased risk of stroke, heart failure, and other cardiovascular complications.
Closed Loop Stimulation (CLS) is an advanced pacemaker feature designed to provide more physiological heart rate adaptation by continuously monitoring cardiac contractility and adjusting the pacing rate accordingly. In previous studies, including the B3 trial, CLS demonstrated a reduction in DDAF incidence in patients with SND. However, this benefit was not observed in patients with AV block, likely due to the adverse effects of frequent RV pacing.
Conduction system pacing, and in particular left bundle branch area pacing (LBBAP), is an emerging pacing strategy that stimulates the heart's intrinsic conduction pathways, resulting in a more physiological and synchronized ventricular activation. This approach has the potential to reduce the negative effects associated with RV pacing.
The BIO|STREAM.CSP CLS submodule aims to investigate whether the combination of LBBAP and CLS can reduce the incidence of DDAF in patients with both SND and AV conduction disorders in routine clinical practice. The study will follow approximately 150 patients over a 24-month period after pacemaker implantation. Patients included are those enrolled in the BIO|STREAM.CSP registry who receive a de novo dual-chamber pacemaker with activated CLS and LBBAP, and who have no prior history of atrial fibrillation.
The primary objective of this exploratory submodule is to assess the incidence and timing of DDAF episodes following activation of CLS, using device-based diagnostics over the follow-up period. The study will evaluate multiple thresholds of AF episode duration (e.g., ≥6 minutes, ≥6 hours, ≥24 hours, and ≥7 days), as well as the time to first occurrence and overall AF burden. Secondary analyses will explore how CLS modulates heart rate in patients with conduction system pacing, including the distribution of paced and sensed heart rates over time.
As an observational study without a control group, BIO|STREAM.CSP CLS is intended to generate hypothesis-generating, real-world evidence rather than to test a predefined hypothesis. The findings are expected to provide insights into the clinical performance of CLS in combination with LBBAP and to support optimization of device programming strategies.
Overall, this study seeks to improve understanding of how advanced pacing technologies can be used together to deliver more physiological cardiac pacing, with the goal of reducing atrial arrhythmias and improving long-term outcomes in patients requiring permanent pacemakers.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Martina Del Maestro
- Número de teléfono: +393426529214
- Correo electrónico: CLS-CSP-STREAM@biotronik.com
Copia de seguridad de contactos de estudio
- Nombre: Paola Napoli
- Número de teléfono: +393357369277
- Correo electrónico: CLS-CSP-STREAM@biotronik.com
Ubicaciones de estudio
-
-
-
Ústí nad Labem, Chequia
- Aún no reclutando
- Masarykova Nemocnice V Usti Nad Labem
-
Contacto:
- Jíří Holý
- Correo electrónico: jiri.holy@kzcr.eu
-
-
-
-
-
Madrid, España
- Aún no reclutando
- Hospital Universitario 12 de Octubre
-
Contacto:
- Alvaro Marco del Castillo
- Correo electrónico: amarco89@hotmail.com
-
Valencia, España
- Aún no reclutando
- Hospital Universitario La Fe
-
Contacto:
- Óscar Cano Pérez
- Correo electrónico: cano_osc@gva.es
-
-
-
-
-
Budapest, Hungría
- Aún no reclutando
- Semmelweis University
-
Contacto:
- László Gellér
- Correo electrónico: geller.laszlo@kardio.sote.hu
-
Szeged, Hungría
- Aún no reclutando
- University Of Szeged
-
Contacto:
- Tamás Szili-Török
- Correo electrónico: szili-torok.tamas@u-szeged.hu
-
-
-
-
-
Brindisi, Italia
- Aún no reclutando
- Ospedale Di Summa - Perrino
-
Contacto:
- Ennio CL Pisanò
- Correo electrónico: enniopisano@hotmail.com
-
Milan, Italia
- Aún no reclutando
- Niguarda Hospital
-
Contacto:
- Matteo Baroni
- Correo electrónico: bimatteo@gmail.com
-
Novara, Italia
- Reclutamiento
- A.O.U. Maggiore della Carita di Novara
-
Contacto:
- Gabriele Dell'Era
- Número de teléfono: +3903213731
- Correo electrónico: gdellera@gmail.com
-
Piove di Sacco, Italia
- Aún no reclutando
- Ospedale di Piove di Sacco
-
Contacto:
- Leonardo Marinaccio
- Correo electrónico: leonardo.marinaccio@aulss6.veneto.it
-
Roma, Italia
- Aún no reclutando
- Fondazione Policlinico Universitario "Agostino Gemelli" Università Cattolica del Sacro Cuore
-
Contacto:
- Maria Lucia Narducci
- Correo electrónico: marialucia.narducci@policlinicogemelli.it
-
Taranto, Italia
- Aún no reclutando
- SS Annunziata Taranto
-
Contacto:
- Cosimo Mandurino
- Número de teléfono: +390994585111
- Correo electrónico: mandurinocosimo@gmail.com
-
-
-
-
-
Coimbra, Portugal
- Aún no reclutando
- Unidade local de Saúde de Coimbra, EPE - Centro Hospitalar Universitario de Coimbra
-
Contacto:
- Correo electrónico: joaoaferreira29@gmail.com
-
Contacto:
- João Ferreira
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Enrolled in the BIO|STREAM.CSP registry
- Standard indication for dual-chamber pacing due to any form of sinus node disease according to guidelines
- DDD-CLS pacing mode activated
- Either ≥ II degree AV block, or native PR interval ≥ 200 ms at baseline ECG with expected RVP ≥ 20%
Exclusion Criteria:
- Implantation dates back more than 90 days
- History of clinical AF
- Patients intended to receive, or already received a pacing lead for traditional RV pacing, His bundle pacing or right bundle branch pacing
- Upgrade from previous pacemaker system
- Patients transitioning from the BIO|MASTER.CSP study
- DDAF episodes present in the device memory at the time of registration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
DDAF incidence
Periodo de tiempo: From CLS activation to 24 months after implantation
|
Time from CLS activation to the first device-detected atrial fibrillation (DDAF) episode of different duration cutoffs (6 minutes, 6 hours, 24 hours, 7 days) through 24 months of follow-up after implantation
|
From CLS activation to 24 months after implantation
|
|
DDAF burden
Periodo de tiempo: From CLS activation to 24 months after implantation
|
The time from CLS activation to the first day with a DDAF burden ≥1% (≈15 minutes) determined within a follow-up period of 24 months after implantation
|
From CLS activation to 24 months after implantation
|
|
Heart Rate histograms
Periodo de tiempo: At 1 year and 2 years after implantation
|
Heart Rate histograms of sensed and paced beats [% time] at 1-year and 2-year follow-ups
|
At 1 year and 2 years after implantation
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- BA121
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .